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Abstract
Bone-marrow-derived mesenchymal stromal cells (MSCs) have the potential to significantly contribute to skeletal muscle
healing through the secretion of paracrine factors that support proliferation and enhance participation of the endogenous
muscle stem cells in the process of repair/regeneration. However, MSC-derived trophic molecules have been poorly
characterized. The aim of this study was to investigate paracrine signaling effects of MSCs on skeletal myoblasts. It was
found, using a biochemical and morphological approach that sphingosine 1-phosphate (S1P), a natural bioactive lipid
exerting a broad range of muscle cell responses, is secreted by MSCs and represents an important factor by which these
cells exert their stimulatory effects on C2C12 myoblast and satellite cell proliferation. Indeed, exposure to conditioned
medium obtained from MSCs cultured in the presence of the selective sphingosine kinase inhibitor (iSK), blocked increased
cell proliferation caused by the conditioned medium from untreated MSCs, and the addition of exogenous S1P in the
conditioned medium from MSCs pre-treated with iSK further increased myoblast proliferation. Finally, we also demonstrated
that the myoblast response to MSC-secreted vascular endothelial growth factor (VEGF) involves the release of S1P from
C2C12 cells. Our data may have important implications in the optimization of cell-based strategies to promote skeletal
muscle regeneration.
Citation: Sassoli C, Frati A, Tani A, Anderloni G, Pierucci F, et al. (2014) Mesenchymal Stromal Cell Secreted Sphingosine 1-Phosphate (S1P) Exerts a Stimulatory
Effect on Skeletal Myoblast Proliferation. PLoS ONE 9(9): e108662. doi:10.1371/journal.pone.0108662
Editor: Maurilio Sampaolesi, Stem Cell Research Institute, Belgium
Received June 3, 2014; Accepted August 25, 2014; Published September 29, 2014
Copyright:  2014 Sassoli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All data are included within the paper.
Funding: This study was supported by research funding from MIUR (Ministero dell’Istruzione dell’Universita` e della Ricerca)- Italy to E.M., L.F., C.S., S.Z.-O. and the
Ente Cassa di Risparmio di Firenze to E.M. and Fondazione Cassa di Risparmio di Pistoia e Pescia to E.M. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: elisabetta.meacci@unifi.it
. These authors contributed equally to this work.
{ Deceased.
Introduction
Bone-marrow-derived mesenchymal stromal cells (MSCs) are
currently considered among the best candidates in the field of
regenerative medicine. Numerous experimental studies have
shown the beneficial effects of MSC transplantation in tissue and
organ repair/regeneration and clinical trials are actually ongoing
[1–6]. A large body of experimental evidence has shown that
transplantation of MSCs in animal models of muscle injury and
disease has great therapeutic potential [7–10]. Indeed, the systemic
or local administration of MSCs into skeletal muscles subjected to
traumatic injuries such as laceration [7], crush or resection [9–11],
or cardiotoxin injection [8,12], has been demonstrated to
contribute to myofiber formation and to the functional recovery
of the muscle tissue. A considerable increase in the capillary
density and collateral perfusion, associated with a reduction of
myofiber atrophy and disarray, has also been observed in ischemic
skeletal muscles transplanted with MSCs [13,14]. Moreover, there
are studies showing that the injection of MSCs into dystrophic
muscles is capable to restore dystrophin expression [12,15,16],
attenuate the oxidative stress [17] and improve the contractile
function [15]. In most of the reported studies, the therapeutic
effects of MSCs do not seem to be attributed to their
differentiation into resident cell types, but rather to their ability
to release paracrine factors capable of improving the host tissue
microenvironment and stimulate the endogenous mechanisms of
tissue repair [2,18,19]. Therefore, the identification of stem cell
secreted proteins, as well as of their downstream signaling
pathways, is of great biological importance for extending the
studies and ameliorating the results obtained after MSC
transplantation. In this context, we have recently demonstrated
that MSCs stimulate skeletal myoblast proliferation and differen-
tiation through the release of vascular endothelial growth factor
(VEGF) [20]. Indeed, MSCs release VEGF and the treatment with
the selective pharmacological VEGF receptor inhibitor, KRN633,
results in a marked attenuation of the receptor activation and in
the inhibition of C2C12 cell proliferation induced by MSC-
conditioned medium.
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Sphingosine 1-phosphate (S1P) is a natural potent and
multifunctional phospholipid mainly released into circulation by
activated platelets and erythrocytes, but also by different cell types
such as cerebellar astrocytes and glioma cells [21–24]. S1P is
reported to exert a broad range of biological responses in many
cell types including skeletal muscle cells [25–32]. Most of the
known actions of S1P are mediated by a family of five specific G
protein-coupled receptors (S1P1–5) which are present in muscle
cells; their activation by S1P has been shown to promote skeletal
myoblast proliferation, differentiation and survival [24,26,32,33].
In particular, we have recently demonstrated that exogenous S1P
attenuates the muscle damage induced by eccentric contraction,
protecting the muscle fibers from apoptosis and preserving satellite
cell viability and renewal [31].
Because of the proven therapeutic effects of S1P and MSCs in
skeletal muscle healing, in the current study we evaluated whether
MSCs could mediate the stimulation of skeletal myoblast
proliferation through the release of S1P in order to extend and
better define the molecular mechanisms underlying the paracrine
interaction between the two cell types. Here, we demonstrated for
the first time, that MSCs produce and secrete a large amount of
S1P in the culture medium and that this sphingolipid is required
for MSC-mediated effects on muscle C2C12 and satellite cell
proliferation. Because it has been suggested that VEGF may
crosstalk with S1P pathway [34–36], we also investigated the
reciprocal interaction between these factors in stimulating
myoblast proliferation. Our data may contribute to define the
mechanisms by which donor MSCs contribute to muscle repair
and regeneration and to optimize cell therapy for muscle
disorders.
Materials and Methods
Ethics statement
All animal manipulations were carried out according to the
European Community guidelines for animal care (DL 116/92,
application of the European Communities Council Directive of 24
November 1986; 86/609/EEC) and approved by the Committee
for Animal Care and Experimental Use of the University of
Florence. The ethical policy of the University of Florence
conforms to the Guide for the care and use of laboratory animals
of the U.S. National Institutes of Health (NIH Publication No. 85-
23, revised 1996; University of Florence assurance No. A5278-01).
The protocols were communicated to local authorities and to
Italian Ministry of the Health; according to the Italian law (Art.7/
D.lgs 116/92) such procedure doesn’t require Ministry authoriza-
tion. The animals were housed with free access to food and water
and maintained on a 12 h light/dark cycle at 22uC room
temperature (RT). All efforts were made to minimize the animal
suffering and the number of animals sacrificed. Animals were
killed by decapitation.
Cell culture and treatments
Mouse bone marrow mesenchymal stromal cells (MSCs) were
isolated from femura and tibiae of male C2F1 mice, following the
Dobson’s procedure [37], expanded in vitro in low glucose
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
1% L-glutamine, 1% penicillin/streptomycin, 25 mM HEPES,
pyruvate and 20% fetal bovine serum (FBS; Sigma, Milan, Italy),
and characterized as reported previously [20]. In some experi-
ments, these cells were cultured at 37uC in a humidified
atmosphere of 5% CO2, in C2C12 myoblast differentiation
medium (DM) or in muscle satellite culture medium (PM) for
48 h [19] in the absence or in the presence of sphingosine kinase
inhibitor (iSK, 5 mM, Tocris, Bristol, UK) [38], and the
conditioned culture medium (MSC-DM, MSC-DMiSK, MSC-
PM and MSC-PMiSK) was harvested and used for culturing
C2C12 myoblasts or satellite cells, in order to assess MSC
paracrine effects.
Murine C2C12 skeletal myoblasts obtained from American
Type Culture Collection (ATCC, Manassas, VA, USA), were
grown in DMEM supplemented with 10% FBS, 1% L-glutamine,
1% penicillin/streptomycin (Sigma) at 37uC in a humidified
atmosphere of 5% CO2 till reaching 60–80% confluence and
shifted in differentiation medium (DM), containing 2% horse
serum (HS, Sigma).
In order to assess the paracrine effect of MSCs, C2C12 cells
were exposed for 24 h to conditioned medium obtained from
MSCs cultured in myoblast DM for 48 h in the absence (MSC-
DM) or in the presence of 5 mM iSK (MSC-DMiSK). In other set
of experiments, the cells were exposed to sphingosine 1-phosphate
(S1P, 1 mM, Calbiochem, San Diego, CA, USA) for 24 h. In some
experiments C2C12 cells were incubated for 24 h in conditioned
medium obtained by culturing C2C12 myoblasts in DM in the
presence or in the absence of iSK for 48 h.
In order to assess the role of S1P-released by MSCs in VEGF
signaling, C2C12 cells were exposed to MSC-DM or MSC-
DMiSK and treated or not with an ATP competitive inhibitor of
vascular endothelial growth factor receptor (VEGFR) tyrosine
kinase activity (KRN633, 170 nM, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) in the absence or in the presence of 1 mM
S1P.
In other experiments, with the aim to assess the role of SphK/
S1P axis in myoblast proliferation induced by MSC-released
paracrine factors including VEGF, C2C12 myoblasts were
cultured in MSC-DM and treated or not with MK571 (10–
20 mM, Tocris, Bristol, UK) an inhibitor of ABCC1 (MRP1)
transporter, known to regulate S1P export in some cells [39] or
with 5 mM iSK.
To confirm the crosstalk between SphK/S1P axis on VEGF-
induced signaling, C2C12 myoblasts in DM were treated or not
with 10–20 mMMK571 or 5 mM iSK for 24 h in the absence or in
the presence of soluble VEGF (2 ng/ml, Sigma) as reported
previously [20].
Satellite cells were isolated from single myofibers of Extensor
Digitorum Longus (EDL) muscles carefully removed from anes-
thetized (with 50 mg/g zolazepam tiletamine) young adult male
Swiss mice (25–30 g) essentially as described previously [19].
Briefly, EDL muscles, soon after isolation, were digested in 0.2%
collagenase type I in DMEM (Sigma) and then transferred to a
Petri dish containing serum-free DMEM, in which single muscle
fibers were liberated from the muscles, by means a gentle
mechanical trituration with a Pasteur pipette. The intact, viable
muscle fibers were collected and subsequently cultured individu-
ally in Matrigel (BD Biosciences, San Jose, CA, USA) treated 24
well plates, at 37uC in a humidified atmosphere of 5% CO2, in
satellite cell proliferation medium (PM) containing DMEM, 20%
FBS, 10% HS (Sigma), 0.5% chicken embryo extract (Sera
Laboratories International Ltd, Horsted Keynes, UK) plus 1% L-
glutamine and 1% penicillin/streptomycin (Sigma) for 48 h. After
that, the myofibers were removed and the derived satellite cells
were expanded in culture in PM before be used for the
experiments. The cells (P1) were cultured as follows: in PM in
the absence (control) or in the presence of 1 mM S1P (Calbiochem)
or with conditioned medium obtained from MSCs cultured in PM
for 48 h in the absence (MSC-PM) or in the presence of 5 mM iSK
(MSC-PMiSK) stimulated or not with 1 mM S1P for 24 h.
Aliquots of cells at P1 culture passage were seeded on glass
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coverslips and assayed for Pax-7 and vimentin (fibroblast marker)
immunophenotype by confocal microscopy to test the degree of
purity of satellite cell cultures which usually was 80%.
Sphingolipid metabolism
MSCs were plated on 35 mm dishes and cultured in cell culture
medium as described above. At 80% confluence the cells were
shifted in DMEM supplemented with 10% FBS and pulsed with
[3H]Sphingosine (Sph) (0,6 mCi/ml) for 2 h. In other experiments
MSCs were pulsed with [3H]serine (10 mCi/ml) and incubated
with C2C12 cell DM or satellite cell PM in the absence or in the
presence of 5 mM iSK. Cells and media were collected and total
lipids extracted with chloroform/methanol (1:2) as previously
reported [23,38,40]. The phase containing [3H]Sphingolipids,
including [3H]S1P or [3H]ceramide, was evaporated under
nitrogen stream. The fractions containing cellular and extracellu-
lar [3H]S1P were collected and subjected to Thin Layer
Chromatography (TLC) on silica gel plates (Merck, Darmstadt,
Germany), using n-butanol/acetic acid/water (3:1:1, v/v/v) as
solvent system. Cold S1P was added in lipid extraction mixture
and used as internal standard. At the end of the TLC, the silica gel
spot that contained [3H]S1P was scraped off and quantified by
liquid scintillation counting [32,38].
Cell proliferation analysis
Cell counting, [3H]thymidine and EdU (5-ethynyl-29-deoxyur-
idine) incorporation assays were used to determine C2C12 and
satellite cell proliferation.
Cell counting. For cell counting the cells were incubated for
24 h in the specific medium (DM for C2C12 myoblasts and PM
for satellite cells) or exposed to MSC-conditioned medium (C2C12
cells: MSC-DM and MSC-DMiSK; satellite cells: MSC-PM and
MSC-PMiSK) in the presence or in the absence of the specific
compounds as reported in the indicated experiments. After 24 h
cells were trypsinized and counted after Trypan Blue incubation
(0.2%, Sigma) in a Burker chamber by two different operators.
[3H]thymidine incorporation. [3H]thymidine incorpora-
tion assay was performed in the cells cultured as reported above;
the cells were incubated for the last 2 h in the presence of methyl
[3H]thymidine (1–2 mCi/ml) (Perkin Elmer, Monza, Italy) and
then processed using trichloroacetic acid precipitation as reported
previously [41]. The recovered radioactivity was measured in a
beta counter (Beckman Coulter s.r.l., Milano, Italy).
EdU (5-ethynyl-29-deoxyuridine) incorporation. EdU in-
corporation assay was performed by using the fluorescent Click-iT
EdU Cell Proliferation Assay (Life Technologies, Grand Island,
NY, USA) according to manufacturer’s instructions. This assay is
based on the incorporation of the pyrimidine analogue EdU in
place of thymidine into newly synthesized DNA of replicating cells.
Briefly, cells grown on glass coverslips were incubated in the
presence of the provided solution of 10 mM EdU for 24 h. After
that, the cells were washed with PBS, fixed with 0.5% buffered
paraformaldehyde (PFA) for 10 min at RT, permeabilized with
cold acetone for 3 min and then incubated with the Alexa Fluor
488 EdU detection solution for 30 min at RT, protected from
light. After washing, the coverslips containing the labeled cells
were mounted with an antifade mounting medium (Biomeda Gel
mount, Electron Microscopy Sciences, Foster City, CA) and
observed under a confocal Leica TCS SP5 microscope (Leica
Microsystems, Mannheim, Germany) equipped with a HeNe/Ar
laser source for fluorescence measurements and with differential
interference contrast (DIC) optics. The number of the cells with
EdU positive nuclei was evaluated in 10 random 2006200 mm
square microscopic fields (636ocular) in each cell preparation and
expressed as percentage of the total cell number evaluated by
labeling nuclei with PI (See confocal immunofluorescence
paragraph).
Confocal immunofluorescence
Both C2C12 myoblasts and satellite cells grown on glass
coverslips were fixed with 0.5% PFA for 10 min at RT. After
permeabilization with cold acetone for 3 min, the fixed cells were
blocked with 0.5% bovine serum albumin (BSA; Sigma) and 3%
glycerol in PBS for 20 min and then incubated with a rabbit
polyclonal antibody anti-Ki67 (1:100; Santa Cruz Biotechnology)
overnight at 4uC. Fixed satellite cells were also incubated
overnight at 4uC with a mouse monoclonal anti-Pax7 (1:100;
Santa Cruz Biotechnology) and with a goat polyclonal anti-
vimentin (1:40; Sigma). The immunoreactions were revealed by
incubation with specific anti-rabbit or anti-goat Alexa Fluor 488-
conjugated IgG or with anti-mouse Alexa Fluor 568-conjugated
IgG (1:200; Molecular Probes, Eugene, OR, USA) for 1 h at RT.
In some experiments, counterstaining was performed with
propidium iodide (PI, 1:30; Molecular Probes) to reveal nuclei.
Negative controls were carried out by replacing the primary
antibody with non-immune serum; cross-reactivity of the second-
ary antibodies was tested in control experiments in which primary
antibodies were omitted. After washing, the coverslips containing
the immuno-labeled cells were mounted with an antifade
mounting medium (Biomeda Gel mount, Electron Microscopy
Sciences) and observed under a confocal Leica TCS SP5
microscope (Leica Microsystems). Observations were performed
using a Leica Plan Apo 636/1.43NA oil immersion objective.
Series of optical sections (102461024 pixels each; pixel size
204.3 nm) 0.4 mm in thickness were taken through the depth of
the cells at intervals of 0.4 mm. Images were then projected onto a
single ‘extended focus’ image. The number of the cells with Ki67
positive nuclei was evaluated in 10 random 2006200 mm square
microscopic fields (636 ocular) in each cell preparation and
expressed as percentage of the total cell number.
Statistical analysis
Data were reported as mean6SEM. Statistical significance was
determined by one-way ANOVA and Newman-Keuls multiple
comparison test or Student’ t test. A p value#0.05 was considered
significant. Calculations were performed using GraphPad Prism
software (GraphPad, San Diego, CA, USA).
Results
MSCs release S1P in the culture medium
Given that S1P has been reported to act both as an intracellular
second messenger and as an extracellular mediator [42], we first
evaluated by [3H]Sphingosine ([3H]Sph) pulse experiments, the
ability of MSCs to release S1P into the extracellular medium. As
shown in Fig. 1A, [3H]Sph incorporated into MSCs was
metabolized mainly into [3H]S1P and [3H]ceramide (Cer), since
the levels of other sphingoid molecules were not detectable in these
experimental conditions (data not shown). [3H]S1P reduction was
also detected at similar extent in the conditioned culture medium
when MSCs were cultured both in C2C12 cell differentiation
medium (MSC-DM) and satellite cell proliferation medium (MSC-
PM) (Fig. 1B), suggesting the ability of MSCs to release the
bioactive lipid. As shown in the same figure, the synthesis and
extracellular release of [3H]S1P was dependent on sphingosine
kinase (SphK) activity. Indeed, we observed a significant reduction
of approximately 40% in the content of [3H]S1P in the
conditioned medium obtained from MSCs cultured in DM or
Released S1P by MSCs Modulates Myoblast Proliferation
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PM in the presence of the selective SphK inhibitor (5 mM; MSC-
DMiSK and MSC-PMiSK). Similar results were obtained when
MSCs were pulsed with [3H]serine and incubated with DM in the
absence or in the presence of iSK (Table 1).
S1P synthesis and release by MSCs affect skeletal muscle
cell proliferation
We next evaluated whether the S1P released by MSCs could
affect C2C12 and satellite cell proliferation. As reported in Fig. 2
the reduced content of S1P in the conditioned medium obtained
from iSK-treated MSCs (MSC-DMiSK and MSC-PMiSK)
Figure 1. S1P content in [3H]sphingosine-pulsed MSCs. A) [3H]sphingosine (Sph)-derived metabolites in MSCs. MSCs were cultured in DMEM
containing 10% FBS in the presence or in the absence of the selective sphingosine kinase inhibitor (5 mM, iSK) for 24 h and pulsed with [3H]Sph for
2 h. [3H]lipids (S1P; Sph; ceramide, Cer) were extracted from cells and conditioned medium and analyzed by TLC as described in Materials and
Methods Section. B) Extracellular/intracellular [3H]S1P ratio in MSCs. MSCs were cultured in C2C12 myoblast differentiation medium (DM, DMEM
containing 2% horse serum) or in satellite cell proliferation medium (PM) in the absence (MSC-DM, MSC-PM) or in the presence of 5 mM iSK (MSC-
DMiSK, MSC-PMiSK) for 48 h and pulsed with [3H]Sph. [3H]lipids were extracted from the cells (intracellular) and the conditioned medium
(extracellular) and processed as reported above. Note the significant reduction, in the content of [3H]S1P in the medium obtained from MSCs cultured
in the presence of iSK. The results shown are mean6SEM of at least three independent experiments. Significance of difference (Student’s t test): in A
*p,0.05 vs control; in B *p,0.05 vs MSC-DM or MSC-PM.
doi:10.1371/journal.pone.0108662.g001
Table 1. S1P content in lysate and conditioned medium of [3H]serine pulsed MSCs.
MSC-lysate [3H]S1P/[3H]lipids MSC-conditioned medium [3H]S1P/[3H]lipids
Control 0,2160,03 (100%) 0,153760,007 (100%)
iSK 0,1360,02 (62610%) 0,092660,01 (6069,3%)
[3H]lipids were extracted by MSCs cultured in the presence or in the absence (control) of 5 mM sphingosine kinase inhibitor (iSK) and successively pulsed with [3H]serine
for 2 h.
[3H]lipids were separated by TLC as described in Materials and Methods Section.
doi:10.1371/journal.pone.0108662.t001
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attenuated C2C12 and satellite cell proliferation as evaluated by
the cell number counting (Fig. 2A) and [3H]thymidine incorpo-
ration assay (Fig. 2B). In particular, we observed a decrease of 40–
50% of both C2C12 and satellite cell number and DNA synthesis
when the cells were exposed for 24 h to MSC-DMiSK and MSC-
PMiSK, respectively, in comparison to specific control (MSC-DM
and MSC-PM). Successively, we evaluated whether the potential
residual active iSK in the conditioned medium could directly affect
myoblast proliferation. We found no significant difference in
C2C12 cell proliferation cultured for 24 h in the conditioned
medium obtained from C2C12 cells incubated for 48 h in DM in
the absence (C2C12-DM) or in the presence of iSK (C2C12-
DMiSK). In particular, the number of proliferating C2C12 cells
was 6,3560,33 and 5,92 60.36 when the cells were exposed for
24 h to C2C12-DM and C2C12-DMiSK, respectively.
The role played by S1P contained in the conditioned medium
from MSCs in the stimulation of myoblast proliferation was
confirmed by morphological analysis (Fig. 3A–D). Incubation of
C2C12 cells for 24 h with MSC-DM resulted in a significant
increase in EdU incorporation and in the immunostaining for
Ki67, a nuclear marker protein for cell proliferation, as compared
with controls (Fig. 3 A–C). Exposure to MSC-DMiSK blocked by
30–40% the increase in cell proliferation caused by MSC-DM
(Fig. 3A–C). As expected, the addition of exogenous S1P to the
cells cultured with MSC-DM and MSC-DMiSK further increased
C2C12 cell proliferation (Fig. 3A–C, E). Of note, satellite cells
showed a similar behavior (Fig. 3D).
Taken together, these results suggest that the synthesis and
release of S1P may play an important role in the stimulatory effects
of myoblast proliferation mediated by MSC-conditioned medium.
S1P and VEGF released by MSCs regulate C2C12 cell
proliferation
Given that our previous studies have delineated the critical role
of VEGF in regulating myoblast cell growth [20] and numerous
studies in the literature have shown the existence of a cross-talk
between S1P and VEGF signaling [34–36], we next analyzed
whether these two factors, contained in the conditioned medium
obtained from MSCs cultured in DM (MSC-DM), cooperated in
the promotion of myoblast proliferation. To this aim, the
experiments were repeated in C2C12 cells cultured in the
presence of a selective VEGF Receptor (VEGFR) inhibitor,
KRN633 (170 nM). It was found that the blocking of VEGF
signaling attenuated MSC-DM-mediated cell growth to a similar
extent as the reduced level of S1P in the culture medium
(approximately by 40% Fig. 4). Notably, co-targeting the VEGF
and S1P pathways in C2C12 cells by the treatment of the
myoblasts with KRN633 and their exposure to MSC-DMiSK
caused an increase of proliferation inhibition of approximately
30% (Fig. 4), indicating that the two signaling pathways could
independently affect the regulation of myoblast function. This
assumption was confirmed by the data showing that the addition
of exogenous S1P was able to prevent the reduction of cell
proliferation induced by the inhibition of VEGFR or exposure to
MSC-conditioned medium with reduced level of S1P (MSC-
DMiSK) or both experimental conditions (MSC-DMiSK+
KRN633) (Fig. 4). Finally, in order to evaluate whether the
MSC-released factors could regulate C2C12 cell proliferation
through the modulation of SphK/S1P signaling of myoblasts,
C2C12 cells, incubated in MSC-DM, were treated with 20 mM
MK571, a reported S1P transporter inhibitor, or/and with 5 mM
Figure 2. Effect of S1P secreted by MSCs on C2C12 and satellite cell proliferation: cell counting and [3H]thymidine incorporation.
C2C12 or satellite cells isolated from single muscle fibers were cultured in differentiation medium (DM) or satellite cell proliferation medium (PM) or
exposed to MSC-conditioned medium obtained by culturing MSCs for 48 h in DM in the absence (MSC-DM) or in the presence of 5 mM iSK (MSC-
DMiSK), or in PM in the absence (MSC-PM) or in the presence of iSK (MSC-PMiSK), respectively. A) Cell counting. After 24 h of culture the cells were
trypsinized and counted as described in Materials and Methods Section. B) [3H]thymidine incorporation assay. Cells were cultured for the last 2 h in the
presence of methyl [3H]thymidine. C2C12 and satellite cells were processed as described in Materials and Methods Section and the recovered
radioactivity measured in a beta counter. The results shown are mean6SEM of at least three independent experiments performed in duplicates.
Significance of difference (Student’s t test): *p,0.05 vs DM or PM; 1p,0.05 vs MSC-DM or MSC-PM.
doi:10.1371/journal.pone.0108662.g002
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Figure 3. Effect of S1P secreted by MSCs and exogenous S1P on C2C12 and satellite cell proliferation: morphological evaluation
and cell counting. A–D) Morphological evaluation of C2C12 and satellite cell proliferation by EdU incorporation assay and Ki67 expression analysis. A)
Representative superimposed DIC and fluorescence images showing nuclear incorporation of EdU (green) in C2C12 cells cultured for 24 h in
differentiation medium (DM) or exposed to MSC-conditioned medium obtained by culturing MSCs for 48 h in DM in the absence (MSC-DM) or in the
presence of 5 mM iSK (MSC-DMiSK), and stimulated or not with 1 mM S1P (MSC-DM+S1P, MSC-DMiSK+S1P). Scale bar 50 mm. B) Representative
confocal immunofluorescence images of C2C12 cells cultured in the indicated experimental conditions as in A, immunostained with antibodies
against the nuclear protein Ki67 (green). Nuclei are counterstained in red with propidium iodide (PI). Yellow color indicates co-localization between
red and green fluorescence signals. Scale bar 50 mm. C) Quantitative analysis of the percentage of EdU or Ki67 positive C2C12 cell nuclei expressed as
percentage of the total nuclei number. D) Representative confocal immunofluorescence image of satellite cells cultured for 24 h in satellite cell
proliferation medium (PM), fixed and immunostained with antibodies against Pax-7 (red) and Ki67 (green). Yellow color indicates co-localization
between red and green fluorescence signals. Scale bar 50 mm. In the histogram the quantitative analysis of the percentage of Ki67 positive nuclei of
satellite cells cultured for 24 h in PM or exposed to MSC-conditioned medium obtained by culturing MSCs for 48 h in PM in the absence (MSC-PM) or
in the presence of 5 mM iSK (MSC-PMiSK), and stimulated or not with 1 mM S1P (MSC-PM+S1P, MSC-PMiSK+S1P). Data shown are mean6SEM and
represent the results of at least three independent experiments with similar results. E) C2C12 cell counting. C2C12 cells were cultured in MSC-DM or in
MSC-DMiSK and stimulated or not (vehicle) with 1 mM S1P. After 24 h of culture the cells were trypsinized and counted as described in Materials and
Methods Section. The results shown are mean6SEM of at least four independent experiments performed in duplicates. Significance of difference: in C
(one-way ANOVA and Newman-Keuls multiple comparison test), *p,0.05 vs DM, #p,0.05 vs MSC-DM, up,0.05 vs MSC-DMisK; in D (one-way ANOVA
and Newman-Keuls multiple comparison test), *p,0.05 vs PM, #p,0.05 vs MSC-PM, up,0.05 vs MSC-PMisK; in E (Student t test), *p,0.05 vs vehicle.
doi:10.1371/journal.pone.0108662.g003
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iSK and then processed for cell proliferation analyses. Interest-
ingly, the enhanced proliferation induced by the factors released
by MSCs, including VEGF, was significantly reduced by the
inhibition of S1P transport and slightly more by the combined
inhibition of both S1P synthesis and release (Fig. 5A). To confirm
a modulation of SphK/S1P axis by VEGF signaling, C2C12 cells
in DM were treated with 5 mM iSK or 10 mM MK571 prior the
stimulation with 2 ng/ml soluble VEGF and analyzed for Ki67
immunoreactivity. The data reported in Fig. 5B further support
the notion that the SphK/S1P axis is a part of VEGF signaling in
the control of skeletal muscle cell proliferation.
Discussion
In the present study we have provided the first experimental
evidence that bioactive lipid, S1P, is secreted by MSCs and
represents a critical factor by which these cells exert their
stimulatory effects on C2C12 myoblast and satellite cell prolifer-
ation. Notably, cell proliferation was induced by a concentration of
S1P that was in the physiological range [26,32,38,43]. In such a
view our data contribute to the understanding of the paracrine
effects of MSC-based therapy on the host skeletal muscle and
suggest that the release of this sphingolipid by the implanted cells
may be a key point for recruiting host myoblasts to participate in
the muscle repair. The possible clinical relevance of our findings is
highlighted by the following observations: i) skeletal muscle is the
largest organ of the human body and numerous traumatic injuries
and pathologies can affect its functionality [44]; ii) the activity of
the resident muscle stem cells, satellite cells, representing
approximately 2% of the total muscle cells, is severely compro-
mised in degenerative diseases and in volumetric muscle loss [44–
47]; iii) satellite cells, the most obvious cell candidate to be
transplanted for muscle regeneration, have some major criticisms
due to their heterogeneity [48,49], loss of stemness after culturing
[50] scarce cell survival in the host tissue [51] and the inability to
cross the endothelial wall [52], thus restricting their use to local
application and the difficulty of obtaining large numbers of cells
from a donor. Moreover, the fact that S1P is being recognized as a
crucial molecule capable of regulating many fundamental skeletal
muscle processes, involving not only the stimulatory action on
satellite cell growth [31,53–55], but also resistance to fatigue [56],
regulation of muscle contraction [25], protection of the muscle
fibers against injury [31,57] may likely contribute to increase the
need of MSC therapy for skeletal muscle disorders.
Our preliminary studies have delineated the essential role of
VEGF contained in the conditioned medium from MSCs in
regulating C2C12 cell proliferation [20]. Of interest, several levels
of cross-talks have been described between VEGF and S1P in
many types of normal [34–36,58] and malignant cells [35,59–62].
In particular, VEGF has been shown to regulate S1P receptor
expression (S1P1) [34,36,63], enhance S1P-induced Akt activation
[34,35,58] and increase intracellular S1P concentration promoting
the activation of SphK [35,59]. Moreover, there is evidence that
its receptor, VEGF Receptor-2 (VEGFR-2), forms signaling
complex with G-coupled receptor and, more recently, with S1P
receptor isoform, S1P1, to regulate cell function in some cells
[35,60]. On the other hand, S1P stimulates VEGF expression and
secretion in different cell types and phosphorylates and transacti-
vates VEGFR-2 [35,36,58,61].
Here, we demonstrated that S1P produced by MSCs exerts its
action in part through distinct pathways from VEGF-induced
signaling. In fact, our data showed that the simultaneous inhibition
of the two pathways evoked a greater reduction of cell proliferation
as compared to the single inhibition of VEGF signaling or
Figure 4. Effect of VEGF signaling inhibition, MSC-secreted S1P and exogenous S1P on C2C12 cell proliferation. C2C12 cells were
exposed to MSC-conditioned medium obtained by culturing MSCs for 48 h in differentiation medium (DM) in the absence (MSC-DM) or in the
presence of 5 mM iSK (MSC-DMiSK), in the absence and in the presence of KRN633 (170 nM), an ATP competitive inhibitor of VEGFR tyrosine kinase
activity, and stimulated or not with 1 mM S1P and then processed for cell proliferation analyses. A) Confocal immunofluorescence analysis of Ki67
expression in C2C12 cells. Quantitative analysis of the percentage of Ki67 positive nuclei performed on digitized confocal fluorescent images of the
cells immunostained with antibodies against the nuclear protein Ki67. The percentage of Ki67 positive nuclei is expressed as percentage of the total
nuclei number (the nuclei were counterstained with PI). The data shown are mean6SEM and represent the results of at least three independent
experiments with similar results. B) [3H]thymidine incorporation assay. The cells were labeled with methyl [3H]thymidine and processed as reported in
Figure 2B. Significance of difference (one-way ANOVA and Newman-Keuls multiple comparison test) *p,0.05 vs MSC-DM, #p,0.05 vs MSC-DM+
KRN633, up,0.05 vs MSC-DM+KRN633+S1P; 1p,0.05 vs MSC-DMiSK+KRN633.
doi:10.1371/journal.pone.0108662.g004
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Figure 5. Crosstalk between VEGF and S1P signaling on C2C12 cell proliferation. A) Cell counting. C2C12 cells exposed to DM or
conditioned medium obtained by culturing MSCs for 48 h in C2C12 differentiation medium (MSC-DM) were treated with 20 mM MK571, a reported
S1P transporter inhibitor, or/and with 5 mM iSK for 24 h and trypsinized and then assayed for cell proliferation by cell counting as described in
Materials and Methods Section. B) Confocal immunofluorescence analysis of Ki67 expression in C2C12 cells. Quantitative analysis of the percentage of
Ki67 positive nuclei performed on digitized confocal fluorescent images of C2C12 cells cultured in DM treated or not with 5 mM iSK or with 10 mM
MK571, prior the stimulation or not with soluble 2 ng/ml VEGF for 24 h, fixed and then immunostained with antibodies against the nuclear protein
Ki67. The percentage of Ki67 positive nuclei is expressed as percentage of the total nuclei number (the nuclei were counterstained with PI). The data
shown are mean6SEM and represent the results of at least three independent experiments with similar results. Significance of difference (one-way
ANOVA and Newman-Keuls multiple comparison test): in A, *p,0.05 vs specific control (DM or MSC-DM), 1p,0.05 vs DM; in B, *p,0.05 vs DM; up,
0.05 vs DM+VEGF; #p,0.05 vs DM+iSK; 1p,0.05 vs DM+MK571.
doi:10.1371/journal.pone.0108662.g005
Figure 6. Schematic drawing summarizing the molecular events involved in the promotion of skeletal myoblast proliferation
induced by the MSC paracrine action. MSCs, mesenchymal stromal cells; SphK, sphingosine kinase; S1P, sphingosine 1-phosphate; iSK, SphK
inhibitor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; S1PR, S1P receptor subtypes; KRN633, VEGFR
inhibitor; MK571, S1P transporter inhibitor; NICD, Notch intracellular domain.
doi:10.1371/journal.pone.0108662.g006
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depletion of S1P from MSC-conditioned medium. Moreover, the
addition of exogenous S1P was able to rescue the impairment in
cell proliferation caused by VEGFR-2 inhibition. Notably, the
data presented in this study, also allow to include the SphK/S1P
axis as a potential signaling pathway by which VEGF can regulate
skeletal muscle proliferation suggesting the possible interplay
between the factors present in the conditioned medium from
MSCs. Indeed, inhibition of S1P synthesis or S1P release by
C2C12 cells can prevent their proliferative response to MSC-
conditioned medium.
Thus, we suggest that the ability of MSCs to secrete different
bioactive molecules that can act independently to regulate skeletal
myoblast proliferation may represent a critical issue for the success
of these cells in tissue repair.
In conclusion our findings have provided novel insights into
functional importance of S1P secreted by MSCs in the promotion
of skeletal myoblast proliferation (Fig. 6). These findings beside
improving our understanding of stem cell biology and action
provide a platform for designing new therapeutic approach and
experimental model of cell based therapy for improving skeletal
muscle regeneration.
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